Latest Headlines

31. Ono Pharma Enters Into A Drug Discovery Partnership With Mediar Therapeutics To Create Novel Antibody Therapeutics For Fibro-Inflammatory Diseases 8/6/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced today that it has entered into a drug discovery partnership and option agreement with Mediar Therapeutics, Inc.

32. Greenstone Biosciences Receives NIH R61 Grant To Advance Cardiac Fibrosis Therapeutics For Duchenne Muscular Dystrophy 8/6/2026

    Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH).

33. Clarivate Scales Agentic AI Across Cortellis To Advance Drug Development 8/6/2026

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions.

34. Schrödinger Announces Strategic Collaboration And Software Agreement With Bristol Myers Squibb To Deploy AI Co-Scientist Bunsen For Agentic Drug Discovery 8/5/2026

    Schrödinger, Inc. today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

35. AI-Empowered Pipeline-In-A-Drug Option: Insilico Medicine Nominates ISM9077, Potential First-In-Class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging 8/5/2026

    Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular diseases including dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease.

36. IQVIA And Medera To Advance Cardiac Gene Therapy And Human-Based Drug Discovery 8/4/2026

    IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.

37. Phylo And Chugai Partner To Advance AI Agents In Drug Discovery 8/4/2026

    Phylo, Inc. today announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows.

38. Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation For The Treatment Of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer 8/3/2026

    Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test.

39. Aravax Awarded FDA Fast Track Designation For PVX108, A Next-Generation Immunotherapy For The Treatment Of Peanut Allergy 8/3/2026

    Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy.

40. U.S. FDA Grants Orphan Drug Designation To Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (NECs) 8/3/2026

    Zai Lab Limited today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs).